Quantcast
Last updated on April 23, 2014 at 12:06 EDT

Latest HIV vaccine Stories

2014-04-01 04:20:52

Immunotherapy and Vaccine Leader Also Promotes Three Executives in Legal, Clinical and Investor Relations BLUE BELL, Pa., April 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support...

2014-03-31 20:21:42

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine) has announced the addition of the "HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" [http://www.researchandmarkets.com/research/hnfpj3/hiv_vaccine ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become...

2014-03-26 04:20:59

Biotech Judged First-in-Class for Cervical Pre-Cancer Immunotherapy (VGX-3100), Which Reports Phase II Results Mid-year 2014 BLUE BELL, Pa., March 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic...

2014-03-15 23:00:37

ReportsnReports.com adds “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” reports to its vast collection of research databases. Dallas, Texas (PRWEB) March 15, 2014 Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and...

2014-03-12 04:21:10

BLUE BELL, Pa., March 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call and live webcast to report its fourth quarter and year end 2013 financial results on Monday, March 17, 2014 at 8:30 a.m. ET. Management will provide an update on the company, discuss fourth quarter and year end results, and discuss expectations for 2014. The audio presentation will be broadcast online at...

2014-03-10 08:30:12

Multi-center collaboration aims to advance neutralizing antibody research from preclinical to clinical trials. SEATTLE, March 10, 2014 /PRNewswire/ -- Seattle BioMed today announced that it has received a seven year Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that would elicit broadly neutralizing antibodies against HIV-1. Seattle BioMed will lead a consortium...

2014-03-04 12:25:30

BLUE BELL, Pa., March 4, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"), today closed its previously announced underwritten public offering of 21,810,900 shares of the Company's common stock, including 2,844,900 shares of common stock issued pursuant to the underwriter's exercise of its overallotment option, at the public offering price of $2.90 per share. The gross proceeds of this offering were approximately $63.3 million. Net proceeds...

2014-02-27 08:30:25

BLUE BELL, Pa., Feb. 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"), today announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The...

2014-02-26 16:28:53

BLUE BELL, Pa., Feb. 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be...

2014-02-19 04:22:25

BLUE BELL, Pa., Feb. 19, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview of the company at the Cowen and Company 34th Annual Health Care Conference in Boston, MA. Cowen and Company 34th Annual Health Care Conference March 3-5, 2014Boston Marriott Copley PlaceBoston, MA Inovio PresentationMonday, March 3(rd)2:50 PM ET A live and archived webcast of Dr. Kim's presentation...